CN118488962A - 用于治疗p53介导的癌症的组合物和方法 - Google Patents
用于治疗p53介导的癌症的组合物和方法 Download PDFInfo
- Publication number
- CN118488962A CN118488962A CN202280081375.8A CN202280081375A CN118488962A CN 118488962 A CN118488962 A CN 118488962A CN 202280081375 A CN202280081375 A CN 202280081375A CN 118488962 A CN118488962 A CN 118488962A
- Authority
- CN
- China
- Prior art keywords
- fusion protein
- sequence
- malignant neoplasms
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253759P | 2021-10-08 | 2021-10-08 | |
| US63/253759 | 2021-10-08 | ||
| PCT/US2022/077779 WO2023060248A1 (en) | 2021-10-08 | 2022-10-07 | Compositions and methods for the treatment of p53-mediated cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118488962A true CN118488962A (zh) | 2024-08-13 |
Family
ID=83995572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280081375.8A Pending CN118488962A (zh) | 2021-10-08 | 2022-10-07 | 用于治疗p53介导的癌症的组合物和方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240400626A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4413023A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024537178A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118488962A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234720A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023060248A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119684450A (zh) * | 2024-12-25 | 2025-03-25 | 无锡傲锐东源生物科技有限公司 | 抗人bcor蛋白单克隆抗体及其杂交瘤细胞株和应用 |
| CN120966914A (zh) * | 2025-10-21 | 2025-11-18 | 曲阜师范大学 | 一种中华蜜蜂DnaJC28基因及其编码蛋白和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| US6630584B1 (en) * | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| GB0210746D0 (en) * | 2002-05-10 | 2002-06-19 | Medical Res Council | Peptide |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| WO2011097456A2 (en) | 2010-02-05 | 2011-08-11 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP2929045B1 (en) * | 2012-12-05 | 2020-12-02 | SOLA Biosciences LLC | Protein expression enhancing polypeptides |
-
2022
- 2022-10-07 WO PCT/US2022/077779 patent/WO2023060248A1/en not_active Ceased
- 2022-10-07 EP EP22794080.6A patent/EP4413023A1/en active Pending
- 2022-10-07 CN CN202280081375.8A patent/CN118488962A/zh active Pending
- 2022-10-07 US US18/698,820 patent/US20240400626A1/en active Pending
- 2022-10-07 JP JP2024520883A patent/JP2024537178A/ja active Pending
- 2022-10-07 CA CA3234720A patent/CA3234720A1/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119684450A (zh) * | 2024-12-25 | 2025-03-25 | 无锡傲锐东源生物科技有限公司 | 抗人bcor蛋白单克隆抗体及其杂交瘤细胞株和应用 |
| CN119684450B (zh) * | 2024-12-25 | 2025-08-05 | 无锡傲锐东源生物科技有限公司 | 抗人bcor蛋白单克隆抗体及其杂交瘤细胞株和应用 |
| CN120966914A (zh) * | 2025-10-21 | 2025-11-18 | 曲阜师范大学 | 一种中华蜜蜂DnaJC28基因及其编码蛋白和应用 |
| CN120966914B (zh) * | 2025-10-21 | 2025-12-23 | 曲阜师范大学 | 一种中华蜜蜂DnaJC28基因及其编码蛋白和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024537178A (ja) | 2024-10-10 |
| US20240400626A1 (en) | 2024-12-05 |
| CA3234720A1 (en) | 2023-04-13 |
| WO2023060248A1 (en) | 2023-04-13 |
| EP4413023A1 (en) | 2024-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3114621A1 (en) | Frataxin expression constructs having engineered promoters and methods of use thereof | |
| US20240327477A1 (en) | Compositions and methods for the treatment of tdp-43 proteinopathies | |
| US20230234997A1 (en) | Compositions and Methods for the Treatment of Synucleinopathies | |
| CN112225793B (zh) | 一种溶酶体靶向肽及其融合蛋白、携带融合蛋白编码序列的腺相关病毒载体及其应用 | |
| KR20220108216A (ko) | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 | |
| US20230226223A1 (en) | Compositions and Methods for the Treatment of Protein Aggregation Disorders | |
| US20240400626A1 (en) | Compositions and methods for the treatment of p53-mediated cancers | |
| US20250042958A1 (en) | Compositions and methods for the treatment of proteopathies | |
| JP2022512831A (ja) | 網膜疾患の遺伝子治療 | |
| RU2851326C1 (ru) | Композиции и способы лечения нарушений агрегации белков | |
| US20240025954A1 (en) | Compositions and Methods for the Treatment of Alzheimer's Disease | |
| RU2855933C1 (ru) | Композиции и способы для лечения протеинопатий tdp-43 | |
| HK40092059A (en) | Compositions and methods for the treatment of synucleinopathies | |
| HK40087812A (en) | Compositions and methods for the treatment of protein aggregation disorders | |
| HK40088984A (en) | Compositions and methods for the treatment of tdp-43 proteinopathies | |
| KR20260008735A (ko) | 간상체-유래 원뿔세포 생존인자 및 인간 IgK 신호 서열을 인코딩하는 벡터 | |
| JP2011516047A (ja) | Max遺伝子含有ベクター | |
| BR112017017867B1 (pt) | Proteína do capsídeo do vírus adenoassociado modificado (aav), sequência de ácido nucleico, partícula de vetor viral, composição farmacêutica, bem como usos do vetor viral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |